Afamelanotide (MT1)
Scenesse · Melanotan I · MT-I
An α-MSH analog that increases eumelanin production. Approval applies to a specific implant and indication.
Mechanism
Melanocortin-1 receptor agonist
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Adults with erythropoietic protoporphyria
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Community loading schedule | 0.5–1 mg | 0.5–1 mg/day | Once daily for 1–2 weeks | Consistent daily time | Subcutaneous | Community-reported |
| Community maintenance schedule | 0.5–1 mg | 1–3 mg/week | Two or three times weekly | Evenly spaced | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Community-vial arithmetic only: 1 mg equals 0.20 mL (20 U-100 units). This must not be confused with SCENESSE, the regulated 16 mg controlled-release implant administered by a trained professional.
Community reference: The Peptide Catalog community guideImportant: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 0.5–1 mg | Once daily for 1–2 weeks | 3.5–7 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 14–28 mg | 2–3 × 10 mg | 10–20 administrations |
| 8 weeks | 28–56 mg | 3–6 × 10 mg | 10–20 administrations |
| 12 weeks | 42–84 mg | 5–9 × 10 mg | 10–20 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 4–6 mL | 1 × 10 mL |
| 8 weeks | 6–12 mL | 1–2 × 10 mL |
| 12 weeks | 10–18 mL | 1–2 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 28 | 28 |
| 8 weeks | 56 | 56 |
| 12 weeks | 84 | 84 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Labeling describes implant-site reactions and pigmentation changes; approval does not extend to unapproved tanning products.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.